FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jürgen Venitz

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Procedures

Physiology

Drug Interactions

Phenomena

Protein Binding

Co-author Network

Publications

TOP 3
Aditi Mulgaonkar; Dirk Gründemann; Jürgen Venitz; Douglas H Sweet
Human Organic Cation Transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as Disposition Pathways for Fluoroquinolone Antimicrobials.
M A Al Hawaj; J C Barrett; J G Kuhn; E J Martin; M E Nolte; Jürgen Venitz; D F Brophy
Monitoring rFVIII prophylaxis dosing using global haemostasis assays.
Jürgen Venitz; Julia Zack; Martine Allard; Hunter Gillies; Jean Regnault; Christopher Dufton
Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jürgen Venitz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Aditi Mulgaonkar; Dirk Gründemann; Jürgen Venitz; Douglas H Sweet
Human Organic Cation Transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as Disposition Pathways for Fluoroquinolone Antimicrobials.
Antimicrobial agents and chemotherapy 2013;57(6):2705-11.
2013: M A Al Hawaj; J C Barrett; J G Kuhn; E J Martin; M E Nolte; Jürgen Venitz; D F Brophy
Monitoring rFVIII prophylaxis dosing using global haemostasis assays.
Haemophilia : the official journal of the World Federation of Hemophilia 2013;19(3):409-14.
2012: Jürgen Venitz; Julia Zack; Martine Allard; Hunter Gillies; Jean Regnault; Christopher Dufton
Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
Journal of clinical pharmacology 2012;52(12):1784-805.
2012: Aditi Mulgaonkar; Jürgen Venitz; Douglas H Sweet
Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.
Expert opinion on drug metabolism & toxicology 2012;8(5):553-69.
2011: Pallabi Mitra; Jürgen Venitz; Yunyun Yuan; Yan Zhang; Phillip M Gerk
Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(9):1589-96.
2011: Lokesh Jain; Elise C Kohn; Shivaani Kummar; Diane R Mould; Jürgen Venitz; Sukyung Woo; Robert Yarchoan; William L Dahut; Erin R Gardner; Giuseppe Giaccone; William D Figg
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
British journal of clinical pharmacology 2011;72(2):294-305.
2010: Lokesh Jain; Erin R Gardner; Jürgen Venitz; Giuseppe Giaccone; Brett E Houk; William D Figg
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(30):3187-92.
2010: Lokesh Jain; Tristan Sissung; Romano Danesi; Elise C Kohn; William L Dahut; Shivaani Kummar; David Venzon; David J Liewehr; Bevin C English; Caitlin E Baum; Robert Yarchoan; Giuseppe Giaccone; Jürgen Venitz; Douglas K Price; William D Figg
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Journal of experimental & clinical cancer research : CR 2010;29():95.
2009: Lokesh Jain; Craig A Vargo; Romano Danesi; Tristan Sissung; Douglas K Price; David Venzon; Jürgen Venitz; William D Figg
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
Molecular cancer therapeutics 2009;8(9):2496-508.
2009: Jeanny B Aragon-Ching; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Seth M Steinberg; David Draper; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
BJU international 2009;103(12):1636-40.
2009: Gennyne Walker; Arun Mandagere; Christopher Dufton; Jürgen Venitz
The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
British journal of clinical pharmacology 2009;67(5):527-34.
2008: Rebecca Spence; Arun Mandagere; Christopher Dufton; Jürgen Venitz
Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.
Journal of clinical pharmacology 2008;48(12):1451-9.
2008: Lokesh Jain; Erin R Gardner; Jürgen Venitz; William Dahut; William D Figg
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
Journal of pharmaceutical and biomedical analysis 2008;46(2):362-7.
2008: William L Dahut; Charity Scripture; Edwin M Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):209-14.
2007: Nehal J Lakhani; Alex Sparreboom; Xia Xu; Timothy D Veenstra; Jürgen Venitz; William L Dahut; William D Figg
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.
Journal of pharmaceutical sciences 2007;96(7):1821-31.
2007: Jürgen Venitz
Using exposure-response and biomarkers to streamline early drug development.
Ernst Schering Research Foundation workshop 2007;(59):47-63.
2006: Lokesh Jain; Jürgen Venitz; William D Figg
Randomized discontinuation trial of sorafenib (BAY 43-9006).
Cancer biology & therapy 2006;5(10):1270-2.
2006: Nehal J Lakhani; Alex Sparreboom; Jürgen Venitz; William L Dahut; William D Figg
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Anti-cancer drugs 2006;17(8):977-83.
2006: Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin C Ryan; Ivana Gojo; Jürgen Venitz; William D Figg; Alex Sparreboom
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs 2006;24(5):367-75.
2006: Donald F Brophy; Marcus E Carr; Erika J Martin; Jürgen Venitz; Todd W B Gehr
The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.
Journal of clinical pharmacology 2006;46(8):887-94.
2006: Milin R Acharya; Alex Sparreboom; Edward A Sausville; BA Conley; James Doroshow; Jürgen Venitz; William D Figg
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology 2006;57(3):275-81.
2006: William L Dahut; Nehal J Lakhani; James L Gulley; Philip M Arlen; Elise C Kohn; Herb Kotz; Debbie McNally; Allyson L Parr; Diana Nguyen; Sherry X Yang; Seth M Steinberg; Jürgen Venitz; Alex Sparreboom; William D Figg
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer biology & therapy 2006;5(1):22-7.
2005: Milin R Acharya; Alex Sparreboom; Jürgen Venitz; William D Figg
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Molecular pharmacology 2005;68(4):917-32.
2005: Nehal J Lakhani; Erin R Lepper; Alex Sparreboom; William L Dahut; Jürgen Venitz; William D Figg
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(9):1176-82.
2004: Tanyifor M Tohnya; Kyunghwa Hwang; Erin R Lepper; Howard A Fine; William L Dahut; Jürgen Venitz; Alex Sparreboom; William D Figg
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;811(2):135-41.
2004: Nehal J Lakhani; Alex Sparreboom; William L Dahut; Jürgen Venitz; William D Figg
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):289-93.
2004: Milin R Acharya; Jürgen Venitz; William D Figg; Alex Sparreboom
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2004;7(3):195-208.
2004: Kyunghwa Hwang; Milin R Acharya; Edward A Sausville; Suoping Zhai; Eunhee W Woo; Jürgen Venitz; William D Figg; Alex Sparreboom
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):289-94.
2003: Nehal J Lakhani; Jürgen Venitz; William D Figg; Alex Sparreboom
Pharmacogenetics of estrogen metabolism and transport in relation to cancer.
Current drug metabolism 2003;4(6):505-13.
2003: MICHELLE RUDEK-RENAUT; Jürgen Venitz; Yuichi Ando; Eddie Reed; James M Pluda; William D Figg
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
Journal of clinical pharmacology 2003;43(10):1124-35.
2003: Pradeep M Sathe; Jürgen Venitz
Comparison of neural network and multiple linear regression as dissolution predictors.
Drug development and industrial pharmacy 2003;29(3):349-55.
2003: Nehal J Lakhani; Mohamadi A Sarkar; Jürgen Venitz; William D Figg
2-Methoxyestradiol, a promising anticancer agent.
Pharmacotherapy 2003;23(2):165-72.
2002: MICHELLE RUDEK-RENAUT; Jürgen Venitz; William D Figg
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Pharmacotherapy 2002;22(6):705-20.
2002: Brian D Kavanagh; Timothy W Secomb; Richard Hsu; Peck-Sun Lin; Jürgen Venitz; Mark Dewhirst
A theoretical model for the effects of reduced hemoglobin-oxygen affinity on tumor oxygenation.
International journal of radiation oncology, biology, physics 2002;53(1):172-9.
2002: Masahiro Sakagami; Peter R Byron; Jürgen Venitz; Frantisek Rypacek
Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary escalator.
Journal of pharmaceutical sciences 2002;91(2):594-604.
2002: Gordon R Macpherson; Sylvia S W Ng; Nehal J Lakhani; Douglas K Price; Jürgen Venitz; William D Figg
Antiangiogenesis therapeutic strategies in prostate cancer.
Cancer metastasis reviews 2002;21(1):93-106.
2001: Brian D Kavanagh; S R Khandelwal; Rupert K Schmidt-Ullrich; J D Roberts; E G Shaw; A D Pearlman; Jürgen Venitz; K E Dusenbery; Donald J Abraham; M J Gerber
A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
International journal of radiation oncology, biology, physics 2001;49(4):1133-9.
2001: Donald F Brophy; LD Wazny; Todd W B Gehr; T J Comstock; Jürgen Venitz
The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.
Pharmacotherapy 2001;21(2):169-74.
2000: R Yuan; Jürgen Venitz
Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.
International journal of clinical pharmacology and therapeutics 2000;38(5):245-53.
1999: Pradeep M Sathe; Jürgen Venitz; Lawrence J Lesko
Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
Pharmaceutical research 1999;16(6):939-43.
1999: R A Kovelesky; Peter R Byron; Jürgen Venitz
Peptidoleukotriene (PLT) release and absorption from the airways of the isolated perfused guinea pig lung following chemical and antigenic challenge.
Pharmaceutical research 1999;16(2):321-6.
1997: V Jagannathan; Jürgen Venitz
Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
Methods and findings in experimental and clinical pharmacology 1997;19(5):351-62.
1996: Patricia W Slattum; Jürgen Venitz; William H Barr
Comparison of methods for the assessment of central nervous system stimulant response after dextroamphetamine administration to healthy male volunteers.
Journal of clinical pharmacology 1996;36(11):1039-50.
1995: V Jagannathan; C March; Jürgen Venitz
Determination of unbound L-tryptophan in human plasma using high-performance liquid chromatography with fluorescence detection.
Biomedical chromatography : BMC 1995;9(6):305-8.
1995: J G Gillum; M Johnson; S Lavoie; Jürgen Venitz
Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection.
Pharmacotherapy 1995;15(2):251-3.
1994: William R Garnett; Jürgen Venitz; R C Wilkens; G Dimenna
Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin.
The American journal of medicine 1994;96(6A):84S-86S.
1993: Ronald E Polk; D Israel; J Wang; Jürgen Venitz; J Miller; J Stotka
Vancomycin skin tests and prediction of "red man syndrome" in healthy volunteers.
Antimicrobial agents and chemotherapy 1993;37(10):2139-43.